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ABSTRACT
Background: A high level of support for tissue
banking has been identified amongst both the
general public and patients. However, much
debate remains about the regulatory framework
of tissue banks.
Objective: This study explored the views of
haematological cancer patients regarding
tissue banking and how tissue banks should
operate.
Methods: Haematological cancer patients from
three outpatient clinics in Australia completed a
questionnaire examining their preferences for
tissue banking as well as items about their
sociodemographic characteristics, disease and
treatment history.
Results: The majority of participants (95%)
reported being willing to allow their leftover
tissue to be used for medical research. Three
quarters (76%) supported the idea of their
medical record being linked to their tissue
sample, and 77% preferred a blanket (one-off)
consent model for future research use of their
tissue sample. Only 57 (27%) participants had
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been asked to give a tissue sample for research,
98% of whom gave permission.
Conclusion: The majority of haematological
cancer patients are willing to donate their
leftover tissue to a tissue bank and have their
medical records linked to tissue samples and
prefer a one-off consent process. These novel
data from potential donors inform the debate
about how tissue banks might operate.
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INTRODUCTION
Scientific developments in the fields of
genomics and personalised medicine in recent
years have led to novel approaches in the way
cancer is diagnosed and treated. For these
advancements to continue, medical
researchers must have access to large
collections of biospecimens and associated
clinical and demographic data [1]. A tissue
bank is a biorepository of tissue samples
(normally removed as part of a diagnostic
procedure or treatment) and related
information stored for the purposes of
ongoing research. Tissue banks are also
referred to as biobanks [2] and the focus of
this study was on disease-specific tissue banks
(as distinct from population-based biobanks).
The establishment of an increasing number
of tissue banks, both nationally and
internationally, has intensified debate about
the legal and ethical issues surrounding tissue
banking. Like all forms of medical research,
ethical concerns such as autonomy, justice and
beneficence must be considered. Tissue banks
have varying policies regarding issues such as
informed consent, linkage of tissue specimens
to medical records, and specimen ownership
and usage, which can lead to public confusion
and uncertainty about privacy. There is a need
to explore the perceptions of actual and
potential donors regarding these issues in
order to inform the debate about how tissue
banks can most efficiently operate.
Several population-based studies have been
conducted internationally and within Australia
to explore perceptions of the general public
towards tissue banking as well as preferences for
different consent models and data linkage. High
rates of willingness amongst the general public
to donate biospecimens for research have been
reported in US [3, 4], European [5–7] and
Australian [8, 9] studies. A few studies that
have explored preferences regarding linking
samples to medical records have consistently
found that the majority of participants express
support for a model whereby samples are linked
to an individual’s medical record [5, 9].
However, the public’s views regarding
preferred models for consent are more varied.
One recent review identified that rates of
support for broad consent models (one-off
consent that covers all future research with
the tissue) varied from 11% to 72%. Rates of
support for specific consent models (consent
given each time the tissue is used for a new
research study) varied from 3% to 61% [10].
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Compared to research conducted with the
general public, perceptions about tissue
banking amongst cancer patients are less well
studied. Generally, willingness to donate
samples is high, ranging from 84% to 100%
[11–14]. Preferences for consent models seem to
vary depending on the study population as well
as the existing model of consent used by an
institution. One US study found that
preferences differed depending on the hospital
population, with the predominately white
population from one hospital more likely to
prefer one-off consent (65%) compared to the
predominately African American population at
another hospital (38%) [11]. In contrast, a
Dutch study conducted at a hospital in which
an opt-out consent model was used found that
60% of patients preferred the opt-out plus
model that involved receiving verbal and
written information. Only 11% of the
participants in this study preferred a one-off
consent model [13].
In one of the only studies to date that has
focused on the views of haematological cancer
patients, a survey of 89 Canadian leukaemia
patients found almost 60% preferred a one-off
consent model, while 10% preferred for consent
to be given for each new research study [15].
The remainder preferred a tiered consent
model, where researchers provide options on
the types of studies that tissue could and could
not be used for.
While the limited research available suggests
people are willing to donate samples to tissue
banks, opinions about ethical issues such as
consent models and the linkage of samples to
personal medical information are more variable.
Reasons for this variability are not well
understood. Given the increasing use of tissue
banks as a key resource in medical research, the
rules and policies surrounding tissue bank
functioning must be informed by the wishes
of the tissue donors [16].
The diagnosis and treatment of
haematological cancers are fundamentally
different from solid cancers [17]. Depending
on the nature of their disease, haematological
cancer patients may undergo lengthy and
aggressive in-patient treatment, while others
may require outpatient monitoring over many
years, leading to extended contact with the
healthcare system [17]. They are also more
likely to be involved in clinical trials than
patients with other cancer types [18, 19].
These differences in the experience of cancer
may influence haematological cancer patients’
views and preferences regarding tissue banking.
AIMS
This study aimed to explore:
1. The views of haematological cancer patients
regarding tissue banking and preferences for
how tissue banks should operate;
2. Whether preferences for different tissue bank
consent systems, data linkage models and
previous responses to requests for tissue
banking are associated with patient
socio-demographic or disease characteristics.
METHODS
Design and Setting
This cross-sectional study involved three
haematological cancer outpatient treatment
centres located in major metropolitan public
hospitals in Australia. Each participating centre
treated at least 300 haematological cancer
patients per year with a broad spectrum of
haematological cancer diagnoses including
lymphomas, leukaemias and myelomas. Two
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centres were located in capital cities and one in
a major regional city.
Participants
Patients aged 18 years or older with a confirmed
diagnosis of haematological cancer and
attending their second or subsequent
outpatient appointment at one of the
participating clinics were eligible to participate
in the study. Patients could be anywhere along
the cancer trajectory. Those patients who had
insufficient English language ability to
complete the questionnaire, or who were
deemed by clinical staff to be too unwell to
participate or unable to provide informed
consent, were excluded.
Procedure
Human research ethics approval was gained
from the University of Newcastle (approval no.
H-2010-1324) and participating treatment
centres. All procedures followed were in
accordance with the ethical standards of the
responsible committee on human
experimentation (institutional and national)
and with the Helsinki Declaration of 1964, as
revised in 2013. Informed consent was obtained
from all patients for being included in the
study. Potentially eligible cancer patients were
identified by either a haematologist or nurse
from the daily clinic attendance list.
Recruitment of participants and data
collection in the clinic were performed by a
trained research assistant. The research assistant
approached eligible patients while they were
waiting for their appointment with their
haematologist, provided them with written
information about the study and sought
informed written consent. The gender and age
of non-consenters were recorded so that
consent bias could be examined.
Participants were asked to complete two
self-administered pen-and-paper
questionnaires. The first questionnaire
included items about participants’
demographic and disease characteristics.
Participants were given the option to complete
this survey in the clinic while waiting for their
appointment or taking it home and posting it
back to the research team via a supplied reply
paid envelope. Approximately 1 month
following the completion of the first
questionnaire, participants were mailed the
second questionnaire as well as a reply paid
envelope to return it to the research team. The
second questionnaire examined a number of
relevant treatment-related topics, including
tissue banking, which is the focus of this
study. Placing these items in a second
questionnaire reduced participant burden by
reducing the length of each questionnaire and
also made it feasible for participants to
complete the first questionnaire while waiting
for their appointment if they wished.
Participants who did not return the
questionnaire to the research team within
2 weeks were sent a reminder letter. A second
reminder letter was sent if the questionnaire
had not been returned after a further 4 weeks.
MEASURES
A full list of questionnaire items administered
in this study is provided in Online Resource 1.
Tissue Banking Preferences
Items on tissue banking were adapted from
those developed by Fleming [9, 20]. A brief
written explanation of what tissue banking
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involved was provided, followed by a series of
ten closed-response questions exploring
preferences about a number of issues including
willingness to allow tissue to be used for
research, linkage of tissue samples to medical
records and consent preferences. It is estimated
that it took participants about 5 min to
complete these questions.
Demographic, Disease and Treatment
Characteristics
Participants self-reported their: age, gender,
marital status, highest level of education,
employment status, country of birth,
residential postcode, type of haematological
cancer, stage of disease progression, time since
diagnosis and types of treatments received.
These items were adapted from current
national data collections [21] and previous
cross-sectional and longitudinal surveys of
cancer populations conducted by the research
group [22, 23]. Postcodes were used to calculate
the geographical remoteness of the participant’s
home using the Accessibility Remoteness Index
of Australia (ARIA) [24].
Statistical Analysis
All statistical analyses were programmed using
SAS v9.4 [25]. Patient characteristics between
participants and non-consenters (age and
gender) were compared, as were those that
answered the second questionnaire and those
that completed the first questionnaire only
(age, gender, education, country of birth and
type of cancer) using Fisher’s exact test.
Estimates of the proportions (and 95% Wald
confidence intervals) are given for the tissue
banking items of interest. We used separate
logistic regression models to assess the effect of
age, gender, place of birth, education
completed, type of cancer and time since
diagnosis on: (1) consent model preferences,
(2) data linkage preferences and (3) previous
permission given for tissue banking. Variables
with a p value\0.2 in the univariate model were
included in the final multivariate adjusted
model. Adjusted odds ratios (OR), 95% CIs and
p-values are reported for variables included in
the final model. All models adjust for treatment
centre as a fixed effect to allow for similar
responses within a treatment centre.
RESULTS
Sample
A total of 395 patients were identified as eligible
to participate in the study. Of these, 353 (89%)
consented to participate. There were no
differences between consenters and
non-consenters in relation to gender (p = 0.72)
and age (p = 0.97). Of those who consented, 289
(82%) returned the first questionnaire, and of
these, 215 (74%) completed the second
questionnaire. There was a significant
difference in the age distribution of those who
completed both questionnaires and those who
completed the first questionnaire only
(p = 0.008). Participants aged 55–74 made up a
higher proportion of the total sample who
completed both questionnaires (58%)
compared to the first questionnaire only
(37%). This article reports data from the 215
participants who completed both the first and
second questionnaires. Table 1 displays the
demographic, disease and treatment
characteristics of the sample.
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Tissue Banking Preferences
Willingness to Donate Tissue
Of the 215 respondents, 95% (n = 198, 95% CI
92–98%) indicated that they would be willing to
allow leftover tissue from amedical procedure to
be used for research. Sevenparticipants indicated
it would depend on the type of tissue (3.3%, 95%
CI1–6%), and four participantswereunwilling to
donate tissue or unsure (2.0%, 95% CI 0–2%). Of
those participants who indicated they would be
willing for their tissue to be used or that it
dependedon the type of tissue, 189 (93%, 95%CI
90–97%) reported that they would agree to any
remaining tissue being stored for future research,
while 13 (6.4%, 95%CI 3–10%)were unsure, and
one (0.5%, 95% CI 0–1%) would not agree.
Consent Model Preferences
Table 2 shows preferences for different consent
models from the 203 respondents. The majority
of the participants (n = 156, 77%, 95% CI
71–83%) indicated a preference to give
permission once to cover all future uses of their
Table 1 Sociodemographic and disease characteristics of





Age at questionnaire completion







Other blood cancers 15 (7.0)







In remission 23 (11)
Do not know 77 (36)
Treatment received
Chemotherapy only 49 (26)
Chemotherapy and other 115 (54)
Other only 26 (12)
No treatment 24 (11)
Marital status
Married or partner 156 (73)
Single, divorced, separated or widowed 56 (26)
Education completed
High school or below 93 (44)
Table 1 continued
Characteristic N (%)a
Vocational training 68 (32)
University degree 52 (24)
Employment status
Paid employment 77 (36)




Other English-speaking country 29 (14)
Other non-English-speaking country 31 (15)
a Not all columns sum to 215 because of missing data
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tissue. A minority of participants (n = 47, 23%,
95% CI 17–28%) preferred for permission to be
given each time or were unsure. Multivariable
analysis revealed that participants born in a
non-English speaking country were significantly
more likely to want to give permission each time
their sample was used or be unsure about how
often they wished to give consent compared to
participants born in Australia.
Preference for Sample Linkage
Of the 207 respondents, a high proportion
(n = 158, 76%, 95% CI 71–82%) also indicated
that they would be willing for information from
their medical record to be linked to their tissue
sample. Only a small proportion of participants
(n = 14, 7%, 95% CI 3–10%) indicated they
would want their samples to remain unlinked,
with the remainder indicating they had no
preference (n = 35, 17%, 95% CI 12–22%). Age
was significantly associated with a preference
for data linkage, with participants aged 55–74
more likely than those aged less than 55 to
indicate they would allow their sample to be
linked to their medical record (as shown in
Table 3).














65 (75) 22 (25) Reference
University 37 (71) 15 (29) 0.84 0.36, 1.94 0.68
Vocational
training
54 (84) 10 (16) 1.74 0.72, 4.21 0.22
Country of birth
Australia 116 (81) 27 (19) Reference
Other English
speaking
23 (79) 6 (21) 0.85 0.30, 2.42 0.76
Non-English
speaking
17 (55) 14 (45) 0.31 0.13, 0.74 0.008*
Type of cancer
Lymphoma 65 (73) 24 (27) Reference
Leukaemia 38 (75) 13 (25) 1.19 0.52, 2.71 0.67
Myeloma 42 (84) 8 (16) 2.31 0.89, 5.99 0.08
Other 11 (85) 2 (15) 2.10 0.42, 10.50 0.37
* Signiﬁcant at p\0.05
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Factors Influencing Decisions About Tissue
Banking
The factors that participants agreed would have
the greatest influence on their decision about
allowing their tissue to be used for research were
‘‘a sense of duty as a citizen’’ (n = 197/205, 96%,
95% CI 93–99%), ‘‘possible benefits to my own
health’’ (n = 175/184, 95%, 95% CI 92–98%)
and ‘‘possible benefits to my family’s health’’
(n = 172/184, 94%, 95% CI 90–97%).
Participants were less concerned about how
their decision would affect their relationship
with their health care team (n = 9/177, 5.1%,
95% CI 2–8%) or the health care provided to
them (n = 13/177, 7.3%, 95% CI 4–11%).
Additional results describing participants’
preferences for (1) the types of funded studies
that could access tissue samples and (2) the
location of tissue sample storage and research
are shown in Online Resource 1.
Preferences for Provision of Study Results
A total of 87% of participants (n = 168/193,
95% CI 82–92%) indicated they would prefer to
receive general information regarding the
results of the study that used their tissue
sample, and 79% (n = 140/177, 95% CI
73–85%) of participants indicated they would
want to receive information specific to their
tissue sample if available.
Actual Rates of Tissue Donation
Of 211 respondents, 57 (27%, 95% CI 21–33%)
had been asked to give a tissue sample for
research, and 56 (98% of those asked) gave
permission. Older participants and those born
in another non-English speaking country were
less likely to have been asked for permission to
donate a tissue sample; however the effects were
not significant in the multivariable analysis.
DISCUSSION
Consistent with previous studies in the general
population and with cancer patients, the
majority of haematological cancer patients
indicated a willingness to donate leftover
tissue for the purposes of research. However,
only one quarter of the participants in this
study had been asked to donate a tissue sample
to a tissue bank and almost all of those asked
had given permission. This is consistent with
other data showing high levels of consent for
tissue banking amongst cancer patients [14].
Despite the overwhelming support of tissue
banking for future research amongst the study
sample, a small proportion of participants
remained unsure. Some of these patients may
benefit from reassurance from their
haematologist about how their tissue would be
used and by whom, although it is acknowledged








Odds ratio 95% CI p value
Age
Less than 55 38 (67) 19 (33) Reference
55–74 98 (82) 22 (18) 2.28 1.11, 4.69 0.03*
75 or older 22 (73) 8 (27) 1.39 0.52, 3.73 0.51
* Signiﬁcant at p\0.05
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that a diverse range of factors influences
patients’ preferences regarding tissue banking,
and education alone will not be sufficient to
address the hesitation of all patients.
The majority of participants supported a
blanket (one-off) consent model. We found
that country of birth was associated with
consent model preferences, with participants
born in a non-English speaking country more
likely to prefer a model where consent is
provided for each new study or to be unsure
compared to participants born in Australia.
While the current study design does not allow
us to explore why this was the case, it is possible
that the views of some participants were shaped
by previous experiences with the informed
consent process in their countries of birth.
Participants’ views may also have been
influenced by different cultural or religious
views, including beliefs regarding cancer (e.g.,
shame, believing cancer is a curse or
punishment) [26], which may have
implications for the consent model preferred.
Support for linkage of medical record data to
tissue samples was high across the study sample.
There was a significant association between age
and preference for record linkage, with
participants aged 55–74 more likely to prefer
samples to be linked compared to those under
55. This contrasts with Fleming’s previous
finding that increasing age negatively
predicted a preference for medical record
linkage [9]. This may reflect an increasing level
of concern among younger cancer patients
about sharing their medical data and the risks
associated with that; however further research is
necessary to explore this explanation.
Alternatively, it is possible that haematological
cancer patients’ views are slightly different from
the views of the participants in Fleming’s study
(tissue bank donors who encompassed both
solid tumour and haematological cancer
patients as well as a number of healthy donors).
Results of this study also showed that
participants’ decisions to donate to a
disease-specific (cancer) tissue bank were
influenced primarily by altruistic reasons, and
only a minority of participants were concerned
that a refusal to donate would have negative
consequences for their care. The majority of
participants indicated a preference for receiving
general information about the results of studies in
which their sample was used, and over three
quarterswouldwant to receive information about
their sample if available. This presents a logistical
challenge for tissue banks in terms of feasibility
and resources as well as ethical issues regarding
the depth and breadth of information that would
be provided to donors [27]. Putting structures in
place to communicate study findings to thewider
community (such as via a website) may provide
the most efficient and acceptable means of
communicating with donors.
One issue not addressed in the current study
is the possible expectation amongst some
cancer patients that leftover tissue samples
may be routinely kept and used for future
research approved by a Human Research Ethics
Committee. In a submission to the Australian
Law Reform Commission’s ‘‘Essentially Yours’’
Inquiry into the protection of human genetic
information in Australia, the Association of
Australian Medical Research Institutes (AAMRI)
submitted that discarding samples could be
seen as ‘wasteful’ and disrespectful to donors
[28]. It has also been suggested that the consent
process is lengthier and more complicated than
necessary, with many patients wishing to
simply ‘get on with treatment’. Exploring
these views and how they influence patients’
perceptions and expectations is an important
area for future research.
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Several further limitations of this study
should be acknowledged. The majority of
findings reported are based on patient
self-report to hypothetical questions regarding
tissue banking, which does not necessarily
predict future behaviour. Given that almost all
of the sub-samplewhohadpreviously been asked
to donate a tissue sample had consented, it is
likely that the high levels of support for tissue
banking reported by patients in this study would
be reflected in their future behaviour. It is
possible that those participants who completed
both questionnaires may have been more
motivated to contribute to research and
therefore were also likely to have more positive
views about tissue banking compared to those
participants who completed the first
questionnaire only. We did not explore
differences between treatment centres in terms
of patients’ views or previous experience with
tissue bank donation, but this may be of interest
for future studies. The representativeness of the
sample in terms of characteristics such as stage of
disease is unknown as we were unable to obtain
these data for patients who did not consent to
participate. It should also benoted that this study
only included patients with haematological
cancer, so the results are not necessarily
generalisable to other cancer populations.
CONCLUSION
This study adds to the scant data regarding the
views of haematological cancer patients about
tissue banking and their perspectives on some
aspects of the legal framework underpinning
tissue bank operations. Consistent with
previous studies with the general population
and cancer patients, haematological cancer
patients strongly supported the concept of
donating leftover tissue to a tissue bank for
research. This study also demonstrated that
factors such as country of birth and age are
associated with an individual’s preference for
how a tissue bank might operate with respect to
models for informed consent and linkage to
medical records. While the data presented here
are from Australian clinics, many of the
regulatory issues associated with tissue
banking (e.g., consent models) apply to tissue
and biobanks internationally. Therefore, these
findings have the potential to inform the debate
about the regulatory structure of tissue banks
and also provide an impetus for haematologists
to ask patients about tissue bank donation
where facilities are available.
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